
## Vicente Molina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8357500/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Schizophrenia induces abnormal frequency-dependent patterns of dynamic brain network reconfiguration during an auditory oddball task. Journal of Neural Engineering, 2022, 19, 016033.	3.5	3
2	Relation between EEG resting-state power and modulation of P300 task-related activity in theta band in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 116, 110541.	4.8	3
3	Default mode network components and its relationship with anomalous self-experiences in schizophrenia: A rs-fMRI exploratory study. Psychiatry Research - Neuroimaging, 2022, 324, 111495.	1.8	8
4	Neurobiological underpinnings of cognitive subtypes in psychoses: A cross-diagnostic cluster analysis. Schizophrenia Research, 2021, 229, 102-111.	2.0	13
5	Anomalous self-experiences are related to general cognition deficits in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2021, 271, 707-712.	3.2	7
6	Editorial: New Developments With Magnetoelectrical Techniques in Schizophrenia. Frontiers in Psychiatry, 2021, 12, 733033.	2.6	0
7	Analysis of the functional EEG network in an Ecuadorian schizophrenia sample. European Journal of Psychiatry, 2021, 35, 216-216.	1.3	0
8	Event-related potentials associated to N-back test performance in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110347.	4.8	3
9	Búsqueda de fenotipos basados en el rendimiento cognitivo en el Trastorno del espectro autista. Revista De PsiquiatrAa Infanto-Juvenil, 2021, 38, 24-32.	0.3	0
10	Search for schizophrenia and bipolar biotypes using functional network properties. Brain and Behavior, 2021, , e2415.	2.2	3
11	Analysis of KCNH2 and CACNA1C schizophrenia risk genes on EEG functional network modulation during an auditory odd-ball task. European Archives of Psychiatry and Clinical Neuroscience, 2020, 270, 433-442.	3.2	5
12	Connectivity strength of the EEG functional network in schizophrenia and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 98, 109801.	4.8	28
13	Altered gamma band noise power in schizophrenia and bipolar patients during a cognitive task. European Journal of Psychiatry, 2020, , .	1.3	4
14	Abnormal self-experiences related to a hypersynchronic brain state in schizophrenia. Schizophrenia Research, 2020, 222, 538-540.	2.0	2
15	ldentificacion of MRI-based psychosis subtypes: Replication and refinement. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 100, 109907.	4.8	15
16	Deficits of entropy modulation of the EEG: A biomarker for altered function in schizophrenia and bipolar disorder?. Journal of Psychiatry and Neuroscience, 2020, 45, 322-333.	2.4	15
17	Función ejecutiva, lenguaje pragmático y perfiles psicopatológicos según la CBCL en niños con trastornos del neurodesarrollo y antecedentes familiares de esquizofrenia. Revista De PsiquiatrÃa Infanto-Juvenil, 2020, 37, 5-16.	0.3	2
18	Social cognition in psychosis: Predictors and effects of META-cognitive training. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 94, 109672.	4.8	2

#	Article	IF	CITATIONS
19	Structural connectivity in schizophrenia and bipolar disorder: Effects of chronicity and antipsychotic treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 369-377.	4.8	12
20	Topography of activation deficits in schizophrenia during P300 task related to cognition and structural connectivity. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 419-428.	3.2	8
21	Deficits of entropy modulation in schizophrenia are predicted by functional connectivity strength in the theta band and structural clustering. NeuroImage: Clinical, 2018, 18, 382-389.	2.7	26
22	Relations between structural and EEGâ€based graph metrics in healthy controls and schizophrenia patients. Human Brain Mapping, 2018, 39, 3152-3165.	3.6	28
23	Early neglect associated to prefrontal structural disconnectivity in schizophrenia. Schizophrenia Research, 2018, 192, 487-488.	2.0	6
24	Quantification of Graph Complexity Based on the Edge Weight Distribution Balance: Application to Brain Networks. International Journal of Neural Systems, 2018, 28, 1750032.	5.2	34
25	Altered predictive capability of the brain network EEG model in schizophrenia during cognition. Schizophrenia Research, 2018, 201, 120-129.	2.0	24
26	Scalar diffusion-MRI measures invariant to acquisition parameters: A first step towards imaging biomarkers. Magnetic Resonance Imaging, 2018, 54, 194-213.	1.8	9
27	Parkinsonism is associated to fronto-caudate disconnectivity and cognition in schizophrenia. Psychiatry Research - Neuroimaging, 2018, 277, 1-6.	1.8	13
28	Deficit of entropy modulation of the EEG in schizophrenia associated to cognitive performance and symptoms. A replication study. Schizophrenia Research, 2018, 195, 334-342.	2.0	20
29	Variation at NRG1 genotype related to modulation of small-world properties of the functional cortical network. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 25-32.	3.2	4
30	Exploring non-stationarity patterns in schizophrenia: neural reorganization abnormalities in the alpha band. Journal of Neural Engineering, 2017, 14, 046001.	3.5	29
31	Functional EEG network analysis in schizophrenia: Evidence of larger segregation and deficit of modulation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 116-123.	4.8	36
32	Alterations in prefrontal connectivity in schizophrenia assessed using diffusion magnetic resonance imaging. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 107-115.	4.8	22
33	Biological and cognitive correlates of cortical curvature in schizophrenia. Psychiatry Research - Neuroimaging, 2017, 270, 68-75.	1.8	12
34	Tianeptina: Â;por qué en España no ha sido catalogada como estupefaciente?. Revista De PsiquiatrÃa Y Salud Mental, 2016, 9, 176-177.	1.8	5
35	Elevated midline-parietal gamma band noise power in schizophrenia but not in bipolar patients. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 743-753.	3.2	9
36	Novel measure of the weigh distribution balance on the brain network: Graph complexity applied to		3

schizophrenia. , 2016, 2016, 700-703.

#	Article	IF	CITATIONS
37	Association between electroencephalographic modulation, psychoticâ€like experiences and cognitive performance in the general population. Psychiatry and Clinical Neurosciences, 2016, 70, 286-294.	1.8	9
38	Relationship between subclinical psychotic symptoms and cognitive performance in the general population. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2016, 9, 78-86.	0.3	4
39	Noise power associated with decreased task-induced variability of brain electrical activity in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2016, 266, 55-61.	3.2	15
40	Modulation of brain network parameters associated with subclinical psychotic symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 66, 54-62.	4.8	5
41	Impulsividad en pacientes migrañosos: estudio en una serie de 155 casos. NeurologÃa, 2016, 31, 599-605.	0.7	10
42	Identification of two clusters within schizophrenia with different structural, functional and clinical characteristics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 64, 79-86.	4.8	23
43	Auditory P3a and P3b neural generators in schizophrenia: An adaptive sLORETA P300 localization approach. Schizophrenia Research, 2015, 169, 318-325.	2.0	37
44	Neural Network Reorganization Analysis During an Auditory Oddball Task in Schizophrenia Using Wavelet Entropy. Entropy, 2015, 17, 5241-5256.	2.2	34
45	A comparative study of event-related coupling patterns during an auditory oddball task in schizophrenia. Journal of Neural Engineering, 2015, 12, 016007.	3.5	49
46	Decreased entropy modulation of EEG response to novelty and relevance in schizophrenia during a P300 task. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 525-535.	3.2	31
47	Gamma Power and Cognition in Patients with Schizophrenia and Their First-Degree Relatives. Neuropsychobiology, 2014, 69, 120-128.	1.9	17
48	Contribution of baseline body mass index and leptin serum level to the prediction of early weight gain with atypical antipsychotics in schizophrenia. Psychiatry and Clinical Neurosciences, 2014, 68, 127-132.	1.8	15
49	Structural correlates of cognitive deficit and elevated gamma noise power in schizophrenia. Psychiatry and Clinical Neurosciences, 2014, 68, 206-215.	1.8	10
50	Frontal gamma noise power and cognitive domains in schizophrenia. Psychiatry Research - Neuroimaging, 2014, 221, 104-113.	1.8	20
51	Decreased spectral entropy modulation in patients with schizophrenia during a P300 task. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 533-543.	3.2	41
52	Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia. Schizophrenia Research, 2014, 158, 223-229.	2.0	25
53	Cognitive outcome and gamma noise power unrelated to neuregulin 1 and 3 variation in schizophrenia. Annals of General Psychiatry, 2014, 13, 18.	2.7	5
54	Graph-Theoretical Analysis in Schizophrenia Performing an Auditory Oddball Task. IFMBE Proceedings, 2014, , 799-802.	0.3	1

#	Article	IF	CITATIONS
55	Randomized trial of clozapine vs. risperidone in treatment-naÃ⁻ve first-episode schizophrenia: Results after one year. Schizophrenia Research, 2013, 149, 156-161.	2.0	33
56	Limbic hyperactivity associated to verbal memory deficit in schizophrenia. Journal of Psychiatric Research, 2013, 47, 843-850.	3.1	7
57	Chronic administration of risperidone in a rat model of schizophrenia: A behavioural, morphological and molecular study. Behavioural Brain Research, 2013, 242, 178-190.	2.2	9
58	A Proposal for Reframing Schizophrenia Research. Journal of Nervous and Mental Disease, 2013, 201, 744-752.	1.0	9
59	Spatial distribution and cognitive correlates of gamma noise power in schizophrenia. Psychological Medicine, 2013, 43, 1175-1185.	4.5	25
60	Elevated noise power in gamma band related to negative symptoms and memory deficit in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 38, 270-275.	4.8	22
61	Convergent evidence of the contribution of TP53 genetic variation (Pro72Arg) to metabolic activity and white matter volume in the frontal lobe in schizophrenia patients. NeuroImage, 2011, 56, 45-51.	4.2	19
62	Prepulse inhibition of the startle reflex in schizophrenia remains stable with short-term quetiapine. European Psychiatry, 2011, 26, 271-275.	0.2	6
63	Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 407-416.	3.2	24
64	Different gray matter patterns in chronic schizophrenia and chronic bipolar disorder patients identified using voxel-based morphometry. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 313-322.	3.2	42
65	No association between prepulse inhibition of the startle reflex and neuropsychological deficit in chronic schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 609-615.	3.2	9
66	Voxel-based morphometry comparison between first episodes of psychosis with and without evolution to schizophrenia. Psychiatry Research - Neuroimaging, 2010, 181, 204-210.	1.8	12
67	Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry. Psychiatry Research - Neuroimaging, 2010, 184, 16-22.	1.8	34
68	Association between cerebral metabolic and structural abnormalities and cognitive performance in schizophrenia. Psychiatry Research - Neuroimaging, 2009, 173, 88-93.	1.8	27
69	Chronic administration of risperidone to healthy rats: A behavioural and morphological study. Behavioural Brain Research, 2009, 205, 488-498.	2.2	15
70	Correlation between prepulse inhibition and cortical perfusion during an attentional test in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 53-61.	4.8	13
71	Biochemical changes in the cingulum in patients with schizophrenia and chronic bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 394-401.	3.2	17
72	Gray matter deficits in bipolar disorder are associated with genetic variability at interleukinâ€1 beta gene (2q13). Genes, Brain and Behavior, 2008, 7, 796-801.	2.2	54

#	Article	IF	CITATIONS
73	Differential clinical, structural and P300 parameters in schizophrenia patients resistant to conventional neuroleptics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 257-266.	4.8	29
74	Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 948-954.	4.8	23
75	A 12-month, open-label, comparative study of quetiapine and risperidone in the acute and long-term treatment of schizophrenia. International Clinical Psychopharmacology, 2008, 23, 138-149.	1.7	11
76	Marked Hypofrontality in Clozapine-responsive Patients. Pharmacopsychiatry, 2007, 40, 157-162.	3.3	26
77	Changes in Cortical Volume with Olanzapine in Chronic Schizophrenia. Pharmacopsychiatry, 2007, 40, 135-139.	3.3	15
78	Dorsolateral prefrontal <i>N</i> -acetyl-aspartate concentration in male patients with chronic schizophrenia and with chronic bipolar disorder. European Psychiatry, 2007, 22, 505-512.	0.2	56
79	Effect of interleukin-1β gene functional polymorphism on dorsolateral prefrontal cortex activity in schizophrenic patients. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1090-1093.	1.7	28
80	Dorsolateral prefrontal and superior temporal volume deficits in first–episode psychoses that evolve into schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 106-111.	3.2	25
81	No Association between Dorsolateral Prefrontal Gray Matter Deficit and N-Acetyl Aspartate Ratios in Schizophrenia. Neuropsychobiology, 2006, 54, 171-178.	1.9	10
82	Hypofrontality in men with first-episode psychosis. British Journal of Psychiatry, 2005, 186, 203-208.	2.8	34
83	Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia. International Clinical Psychopharmacology, 2005, 20, 13-18.	1.7	21
84	Dorsolateral prefrontal cortex contribution to abnormalities of the P300 component of the event-related potential in schizophrenia. Psychiatry Research - Neuroimaging, 2005, 140, 17-26.	1.8	24
85	Prefrontal atrophy in first episodes of schizophrenia associated with limbic metabolic hyperactivity. Journal of Psychiatric Research, 2005, 39, 117-127.	3.1	49
86	Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology, 2005, 178, 17-26.	3.1	65
87	Association between excessive frontal cerebrospinal fluid and illness duration in males but not in females with schizophrenia. European Psychiatry, 2005, 20, 332-338.	0.2	9
88	Ventricular enlargement in schizophrenia is associated with a genetic polymorphism at the interleukin-1 receptor antagonist gene. NeuroImage, 2005, 27, 1002-1006.	4.2	46
89	N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration. Schizophrenia Research, 2005, 73, 209-219.	2.0	58
90	Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophrenia Research, 2005, 80, 61-71.	2.0	99

#	Article	IF	CITATIONS
91	Asociación entre mayor cantidad de lÃquido cefalorraquÃdeo frontal y duración de la enfermedad en varones pero no en mujeres con esquizofrenia. European Psychiatry (Ed Española), 2005, 12, 439-445.	0.0	0
92	Structural effects of atypical antipsychotics: Implications for the meaning of cortical volume deficit in schizophrenia. European Journal of Psychiatry, 2005, 19, .	1.3	0
93	Long-Term Olanzapine Treatment and P300 Parameters in Schizophrenia. Neuropsychobiology, 2004, 50, 182-188.	1.9	24
94	Lower prefrontal gray matter volume in schizophrenia in chronic but not in first episode schizophrenia patients. Psychiatry Research - Neuroimaging, 2004, 131, 45-56.	1.8	42
95	An electrophysiological (ERP) component, the recognition potential, in the assessment of brain semantic networks in patients with schizophrenia. Schizophrenia Research, 2004, 71, 393-404.	2.0	8
96	Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia. International Clinical Psychopharmacology, 2004, 19, 221-228.	1.7	18
97	Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry Research - Neuroimaging, 2003, 122, 125-135.	1.8	53
98	Anatomical and functional cerebral variables associated with basal symptoms but not risperidone response in minimally treated schizophrenia. Psychiatry Research - Neuroimaging, 2003, 124, 163-175.	1.8	34
99	Anatomical and functional brain variables associated with clozapine response in treatment-resistant schizophrenia. Psychiatry Research - Neuroimaging, 2003, 124, 153-161.	1.8	70
100	Cerebral metabolism and risperidone treatment in schizophrenia. Schizophrenia Research, 2003, 60, 1-7.	2.0	41
101	Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. NeuroImage, 2003, 19, 601-612.	4.2	125
102	Association between relative temporal and prefrontal sulcal cerebrospinal fluid and illness duration in schizophrenia. Schizophrenia Research, 2002, 58, 305-312.	2.0	21
103	Multimodal neuroimaging studies and neurodevelopment and neurodegeneration hypotheses of schizophrenia. Neurotoxicity Research, 2002, 4, 437-451.	2.7	5
104	P300 amplitude as a possible correlate of frontal degeneration in schizophrenia. Schizophrenia Research, 2001, 49, 121-128.	2.0	40
105	Auditory P300 event related potential and serotonin reuptake inhibitor treatment in obsessive-compulsive disorder patients. Psychiatry Research, 2001, 101, 75-81.	3.3	57
106	<title>Multimodality image quantification using the Talairach grid</title> . , 2001, , .		28
107	The Wisconsin Card Sorting Test and the assessment of frontal function in obsessive-compulsive patients: An event-related potential study. Cognitive Neuropsychiatry, 2001, 6, 109-129.	1.3	11
108	Cerebral perfusion correlates of negative symptomatology and parkinsonism in a sample of treatment-refractory schizophrenics: an exploratory 99mTc-HMPAO SPET study. Schizophrenia Research, 1997, 25, 11-20.	2.0	33

#	Article	IF	CITATIONS
109	Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A99mTc-HMPAO study. Psychiatry Research - Neuroimaging, 1997, 76, 51-61.	1.8	51
110	The Wisconsin Card Sorting Test and the assessment of frontal function: A validation study with event-related potentials. Neuropsychologia, 1997, 35, 399-408.	1.6	86
111	El estudio de las funciones cognitivas superiores mediante cartografÃa eléctrica cerebral computadorizada: criterios de rigor técnico y metodológico. Estudios De Psicologia, 1996, 17, 27-44.	0.3	2
112	Cerebral Perfusion, Electrical Activity and Effects of Serotonergic Treatment in Obsessive-Compulsive Disorder. Neuropsychobiology, 1995, 32, 139-148.	1.9	36
113	Effect of the normalization template in statistical parametric mapping of PET scans. , 0, , .		4